Regenxbio (RGNX) Cash & Current Investments (2014 - 2025)

Regenxbio's Cash & Current Investments history runs 12 years deep, the most recent figure standing at $230.1 million for Q4 2025.

• On a quarterly basis, Cash & Current Investments fell 1.97% year-over-year to $230.1 million in Q4 2025; TTM through Dec 2025 was $230.1 million, a 1.97% decrease from a year earlier, with the FY2025 full-year figure at $230.1 million, down 1.97% from the prior year.
• Cash & Current Investments retreated to $230.1 million in Q4 2025 per RGNX's latest filing, from $274.2 million in the prior quarter.
• Across five years, Cash & Current Investments topped out at $457.4 million in Q4 2021 and bottomed at $230.1 million in Q4 2025.
• The 5-year median for Cash & Current Investments is $327.6 million (2023), against an average of $330.0 million.
• Across the five-year window, Cash & Current Investments soared 57.88% in 2021 and slipped 24.51% in 2023, its largest moves.
• Year by year, Cash & Current Investments stood at $457.4 million in 2021, then fell by 20.29% to $364.6 million in 2022, then declined by 24.51% to $275.3 million in 2023, then slipped by 14.74% to $234.7 million in 2024, then decreased by 1.97% to $230.1 million in 2025.
• Per Business Quant, the three latest RGNX Cash & Current Investments figures stand at $230.1 million (Q4 2025), $274.2 million (Q3 2025), and $323.3 million (Q2 2025).